Details for Patent: 9,549,929

Which drugs does patent 9,549,929 protect, and when does it expire?

Patent 9,549,929 protects CIBINQO and is included in one NDA.

This patent has sixty-five patent family members in forty-four countries.

Summary for Patent: 9,549,929

Title:	Pyrrolo[2,3-D]pyrimidine derivatives
Abstract:	Described herein are pyrrolo{2,3-d}pyrimidine derivatives, their use as Janus Kinase (JAK) inhibitors, and pharmaceutical compositions containing them.
Inventor(s):	Brown; Matthew Frank (Stonington, CT), Fenwick; Ashley Edward (Richland, MI), Flanagan; Mark Edward (Gales Ferry, CT), Gonzales; Andrea (Kalamazoo, MI), Johnson; Timothy Allan (Vicksburg, MI), Kaila; Neelu (Lexington, MA), Mitton-Fry; Mark J. (Granville, OH), Strohbach; Joseph Walter (Wentzville, MO), TenBrink; Ruth E. (Labadie, MO), Trzupek; John David (Medford, MA), Unwalla; Rayomand Jal (Bedford, MA), Vazquez; Michael L. (Billerica, MA), Parikh; Mihir D. (Groton, CT)
Assignee:	Pfizer Inc. (New York, NY)
Application Number:	14/715,046
Patent Claim Types: see list of patent claims	Use; Composition;

Drugs Protected by US Patent 9,549,929

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Pfizer	CIBINQO	abrocitinib	TABLET;ORAL	213871-001	Jan 14, 2022		RX	Yes	No						TREATMENT OF ADULTS WITH REFRACTORY, MODERATE-TO-SEVERE ATOPIC DERMATITIS NOT ADEQUATELY CONTROLLED WITH OTHER SYSTEMIC DRUG PRODUCTS OR WHEN USE OF THOSE THERAPIES IS INADVISABLE
Pfizer	CIBINQO	abrocitinib	TABLET;ORAL	213871-002	Jan 14, 2022		RX	Yes	No						TREATMENT OF ADULTS WITH REFRACTORY, MODERATE-TO-SEVERE ATOPIC DERMATITIS NOT ADEQUATELY CONTROLLED WITH OTHER SYSTEMIC DRUG PRODUCTS OR WHEN USE OF THOSE THERAPIES IS INADVISABLE
Pfizer	CIBINQO	abrocitinib	TABLET;ORAL	213871-003	Jan 14, 2022		RX	Yes	Yes						TREATMENT OF ADULTS WITH REFRACTORY, MODERATE-TO-SEVERE ATOPIC DERMATITIS NOT ADEQUATELY CONTROLLED WITH OTHER SYSTEMIC DRUG PRODUCTS OR WHEN USE OF THOSE THERAPIES IS INADVISABLE

International Family Members for US Patent 9,549,929

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	094857
Australia	2014220357
Brazil	112015019634
Canada	2900703